Literature DB >> 6848557

Reversal of shortened platelet survival in rats by the antifibrinolytic agent, epsilon aminocaproic acid.

P D Winocour, R L Kinlough-Rathbone, M Richardson, J F Mustard.   

Abstract

Platelet survival in rabbits and rats is shortened by placing indwelling catheters in the aorta; this shortening appears to be at least partly related to the extent of vessel wall injury and platelet interaction with the repeatedly damaged wall. Treatment of rabbit platelets with plasmin and other proteolytic enzymes in vitro shortens their survival when they are returned to the circulation. Because platelets may be exposed to plasmin and other proteolytic enzymes in rabbits and rats with indwelling aortic catheters, we examined the effect of epsilon-aminocaproic acid (EACA) on platelet survival in rats. At a dose of 1 g/kg every 4 h, EACA significantly reduced whole blood fibrinolytic activity and prolonged the shortened platelet survival in rats with indwelling aortic catheters. Mean platelet survival for untreated rats with indwelling aortic catheters was 38.6 +/- 1.9 h, and for rats treated with EACA, 53.8 +/- 3.8 h. Scanning electron microscopy showed that the injured vessel wall of these animals was mainly covered with platelets and fibrin, whereas in control animals that did not receive EACA, the injured surface was mainly covered with platelets and little fibrin was observed. Thus shortened platelet survival during continuous vessel wall injury may result from the local generation of plasmin or the release of proteolytic enzymes at sites where platelets (and possibly leukocytes) interact with the vessel wall.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848557      PMCID: PMC436848          DOI: 10.1172/jci110745

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  THROMBOPLASTIC AND FIBRINOLYTIC ACTIVITIES IN VESSELS OF ANIMALS.

Authors:  T ASTRUP; K BULUK
Journal:  Circ Res       Date:  1963-09       Impact factor: 17.367

2.  Adherence of platelets to a collagen-coated surface: development of a quantitative method.

Authors:  J P Cazenave; M A Packham; J F Mustard
Journal:  J Lab Clin Med       Date:  1973-12

3.  Platelet and fibrinogen consumption in man.

Authors:  L A Harker; S J Slichter
Journal:  N Engl J Med       Date:  1972-11-16       Impact factor: 91.245

4.  Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy.

Authors:  H S Weily; E Genton
Journal:  Circulation       Date:  1970-11       Impact factor: 29.690

5.  Platelet survival studies in man. With special reference to thrombosis and atherosclerosis.

Authors:  A F Abrahamsen
Journal:  Scand J Haematol Suppl       Date:  1968

Review 6.  On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.

Authors:  D Collen
Journal:  Thromb Haemost       Date:  1980-06-18       Impact factor: 5.249

7.  The neutral proteases of human granulocytes. Isolation and partial characterization of granulocyte elastases.

Authors:  K Ohlsson; I Olsson
Journal:  Eur J Biochem       Date:  1974-03-01

8.  Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets.

Authors:  N G Ardlie; M A Packham; J F Mustard
Journal:  Br J Haematol       Date:  1970-07       Impact factor: 6.998

9.  Platelet sialic acid and platelet survival after aggregation by ADP.

Authors:  M A Packham; M A Guccione; R L Kinlough-Rathbone; J F Mustard
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

10.  High does epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage.

Authors:  R Glick; D Green; C Ts'ao; W A Witt; A T Yu; A J Raimondi
Journal:  Neurosurgery       Date:  1981-10       Impact factor: 4.654

View more
  1 in total

1.  Plasmin inhibition of platelet function and of arachidonic acid metabolism.

Authors:  A I Schafer; B Adelman
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.